Email Page Print Page

Corporate Governance *



BDSI® Code of Ethical Conduct

On March 24, 2003, BDSI®'s Board of Directors adopted the Code of Ethical Conduct for the company's principal executive and financial officers. (revision: April 2014)


BDSI® Disclosure Policy

BioDelivery Sciences International, Inc. is committed to the fair disclosure of information about the company consistent with the Securities and Exchange Commission's Regulation Fair Disclosure ("Regulation FD").


Audit Committee Charter - Amended July 2014


Nominating and Corporate Governance Committee Charter - Adopted May 19, 2004 


Compensation Committee Charter - Amended July 2014


Lead Director Charter - Adopted July 26, 2007



* Each of our Board committees reviews its charter for potential updates on an annual basis.  In addition, our Board of Directors reviews our company's Code of Ethical Conduct for potential updates on an annual basis.

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development
Previously announced interim data showed pain improvement compared to placebo; results not replicated in patients enrolled post interim analysis

BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Year-End 2014 Financial Results
2014 - A Year of Many Significant Milestones, with More Expected for 2015, as BDSI Continues its Growth as an Integrated Specialty Pharmaceutical Company